Physical and psychosocial function in rheumatoid arthritis. Clinical use of a self-administered health status instrument

1982 ◽  
Vol 142 (5) ◽  
pp. 879-882 ◽  
Author(s):  
R. A. Deyo
Rheumatology ◽  
1994 ◽  
Vol 33 (7) ◽  
pp. 655-662 ◽  
Author(s):  
N. P. HURST ◽  
P. JOBANPUTRA ◽  
M. HUNTER ◽  
M. LAMBERT ◽  
A. LOCHHEAD ◽  
...  

Rheumatology ◽  
1992 ◽  
Vol 31 (2) ◽  
pp. 87-90 ◽  
Author(s):  
R. FITZPATRICK ◽  
S. ZIEBLAND ◽  
C. JENKINSON ◽  
A. MOWAT ◽  
A. MOWAT

2002 ◽  
Author(s):  
H. van Middendorp ◽  
R. Geenen ◽  
M. J. Sorbi ◽  
A.J.J.M. Vingerhoets ◽  
L.J.P. Doornen ◽  
...  

2020 ◽  
Vol 72 (3) ◽  
pp. 301-308
Author(s):  
Joshua F. Baker ◽  
Bryant R. England ◽  
Ted R. Mikuls ◽  
Jesse Y. Hsu ◽  
Michael D. George ◽  
...  

2002 ◽  
Vol 11 (2) ◽  
pp. 75-75
Author(s):  
H.W. van der Werf ◽  
J. Foster ◽  
M. van der Meijden ◽  
T. van der Molen

2015 ◽  
Vol 8 (3) ◽  
pp. 156 ◽  
Author(s):  
Mosharafeh Chaleshgar Kordasiabi ◽  
Maassoumeh Akhlaghi ◽  
Mohammad Hossein Baghianimoghadam ◽  
Mohammad Ali Morowatisharifabad ◽  
Mohsen Askarishahi ◽  
...  

<p><strong>INTRODUCTION:</strong> Rheumatoid Arthritis (RA) is a systemic, autoimmune and inflammatory disease with an unknown etiology that is associated with progressive joint degeneration, limitation of physical activity and disability. The aim of the study was to evaluate self-management behaviors and their associated factors in RA patients.</p><p><strong>MATERIAL &amp; METHOD: </strong>This cross-sectional study was performed in 2013 on185 patients in Iran. Data were selected through convenient sampling. The collected data included demographic variables, disease related variables, Arthritis Impact Measurement Scale 2 (AIMS-2SF), and Self-Management Behaviors (SMB). Data were analyzed by SPSS17 using Spearman correlation and logistic regression test.</p><p><strong>RESULT:</strong> In this study drug management, regular follow-up, and food supplement were used as the most frequently applied SMB and aquatic exercise, diet, massage therapy, and relaxation were the least common SMBs. Age, education, health status, occupation, marital status, sex, DAS28 (Disease Activity Score 28 joints), and PGA (Physician Global Assessment) were significantly related with SMB.</p><p><strong>CONCLUSION:</strong> The result of the study highlight the influence of demographic variables, health status, and disease related data on SMB. Thus, more studies are required to find factors influencing SMB in order to improve SMB.</p>


2007 ◽  
Vol 57 (3) ◽  
pp. 454-460 ◽  
Author(s):  
Turid Heiberg ◽  
Tore K. Kvien ◽  
Øystein Dale ◽  
Petter Mowinckel ◽  
Gerd J. Aanerud ◽  
...  

2020 ◽  
Author(s):  
Li Lin ◽  
Yuan Wang ◽  
Sennan Shao ◽  
Wen Lin ◽  
Dan Huang ◽  
...  

Abstract Background: The combination of traditional Chinese medicine and western medicine is commonly accepted in clinics in China. Shaoyao-Gancao-Fuzi decoction (SGFD) has been extensively used to dispel wind, eliminate dampness and treat paralysis. Tofacitinib is approved for the treatment of rheumatoid arthritis. SGFD and tofacitinib could be used together for the treatment of rheumatoid arthritis.Methods: A cocktail approach was employed to assess the effects of SGFD on the activities of CYP450s. After pretreatment for 2 weeks with SGFD, a cocktail solution was given to rats 24 h after the last dose of saline or SGFD. Additionally, the pharmacokinetic profiles of oral administration of tofacitinib in rats, with or without SGFD pre-treatment were investigated.Results: The results showed that SGFD could induce the activity of CYP1A2 and inhibit the activity of CYP3A4. Furthermore, SGFD could significantly affect the pharmacokinetics of tofacitinib. Compared with control group, the AUC0-∞ of tofacitinib was increased from 13669.53 ± 4986.83 to 28706.69 ± 9563.13 ng/mL*h (p < 0.01), and the Cmax was increased from 8359.66 ± 1512.22 to 11332.51 ± 2791.90 ng/mL (p < 0.05).Conclusions: The system exposure of tofacitinib was increased by SGFD. The mechanism might be through inhibiting the activity of CYP3A4 and reducing the metabolism of tofacitinib in rats. The study will provide better guidance for the safe clinical use of SGFD and tofacitinib.


Sign in / Sign up

Export Citation Format

Share Document